Significantly, PC-9-R, a gefitinib-resistant subline derived from PC-9 (a mutant EGFR-expressing NSCLC cell line sensitive to EGFR-TKIs), showed a higher basal level of glucose uptake compared to that of PC-9 (1.8 pg/105 cells for PC-9-R and 0.56 pg/105 cells for PC-9), which was further increased after gefitinib treatment (Figure 1A). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.